{"id":3622057,"date":"2023-06-05T08:00:00","date_gmt":"2023-06-05T12:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/moderna-and-merck-announce-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-a-statistically-significant-and-clinically-meaningful-improvement-in-distant-metastasis-free\/"},"modified":"2025-03-07T23:41:07","modified_gmt":"2025-03-08T04:41:07","slug":"moderna-and-merck-announce-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-a-statistically-significant-and-clinically-meaningful-improvement-in-distant-metastasis-free","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/moderna-and-merck-announce-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-a-statistically-significant-and-clinically-meaningful-improvement-in-distant-metastasis-free\/","title":{"rendered":"Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA\u00ae (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival (DMFS) in Patients with High-Risk Stage III\/IV Melanoma Following Complete Resection Versus KEYTRUDA"},"content":{"rendered":"<p>&lt;!&#8211; <\/p>\n<p style=\"text-align: center\">\n    <strong>Moderna and Merck Announce mRNA-4157 (V940) in Combination With<br \/>\n      KEYTRUDA<\/strong><strong><sup>\u00ae<\/sup><\/strong><strong><br \/>\n      (pembrolizumab) Demonstrated a Statistically Significant and Clinically<br \/>\n      Meaningful Improvement in Distant Metastasis-Free Survival (DMFS) in<br \/>\n      Patients with High-Risk Stage III\/IV Melanoma Following Complete Resection<br \/>\n      Versus KEYTRUDA<sup>\u00ae<\/sup><br \/>\n    <\/strong>\n  <\/p>\n<p> &#8211;&gt;<\/p>\n<p style=\"text-align: center\">\n    <strong><em>mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of distant<br \/>\n        metastasis or death by 65% (HR=0.347 [95% CI, 0.145-0.828]); one-sided p<br \/>\n        value=0.0063) compared to KEYTRUDA alone<\/em><\/strong>\n  <\/p>\n<p style=\"text-align: center\">\n    <strong><em>The DMFS results, a key secondary endpoint of the Phase 2b KEYNOTE-942<br \/>\n        study, will be presented at the 2023 American Society of Clinical Oncology<br \/>\n        (ASCO) Annual Meeting<\/em><\/strong>\n  <\/p>\n<p style=\"text-align: center\">\n    <strong><em>Companies plan to initiate a Phase 3 study in the adjuvant setting in<br \/>\n        patients with high-risk melanoma in 2023, and rapidly expand to additional<br \/>\n        tumor types, including non-small cell lung cancer<\/em><\/strong>\n  <\/p>\n<p>\n    CAMBRIDGE, M.A. &amp; RAHWAY, N.J., June 5, 2023 \u2013 Moderna, Inc.<br \/>\n    (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA)<br \/>\n    therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the<br \/>\n    United States and Canada, today announced distant metastasis-free survival<br \/>\n    (DMFS) results from the Phase 2b randomized KEYNOTE-942\/mRNA-4157-P201 study,<br \/>\n    a clinical trial evaluating mRNA-4157 (V940), an investigational<br \/>\n    individualized neoantigen therapy (INT), in combination with KEYTRUDA,<br \/>\n    Merck\u2019s anti-PD-1 therapy, in patients with resected high-risk melanoma<br \/>\n    (stage III\/IV). In the overall intention-to-treat (ITT) population, adjuvant<br \/>\n    treatment&nbsp;with mRNA-4157 (V940) in combination with KEYTRUDA demonstrated<br \/>\n    a statistically significant and clinically meaningful improvement in DMFS, a<br \/>\n    key secondary endpoint of the study, compared with KEYTRUDA alone and reduced<br \/>\n    the risk of developing distant metastasis or death by 65% (HR=0.347 [95% CI,<br \/>\n    0.145-0.828]); one-sided p value=0.0063). The secondary endpoint of DMFS,<br \/>\n    defined as the time from the first dose of KEYTRUDA until the date of first<br \/>\n    distant recurrence or death from any cause, was pre-specified for statistical<br \/>\n    testing following the positive primary endpoint of recurrence-free survival<br \/>\n    (RFS). These late-breaking data are being presented for the first time today<br \/>\n    at 5:00 p.m. ET during an oral abstract session at the 2023 American Society<br \/>\n    of Clinical Oncology (ASCO) Annual Meeting (abstract #LBA9503).\n  <\/p>\n<p>\n    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; \u201cWe are excited to be sharing these<br \/>\n    results with the oncology community and thrilled to see such an exceptional<br \/>\n    result in distant melanoma recurrence or death. Patients who experience<br \/>\n    metastases at distant sites typically have worse survival outcomes and a poor<br \/>\n    prognosis, thus these results showing a reduction in the risk of distant<br \/>\n    recurrence underscore the potential of neoantigen therapy,\u201d said Kyle<br \/>\n    Holen, M.D., Moderna\u2019s Senior Vice President and Head of Development,<br \/>\n    Therapeutics and Oncology. \u201cThese results add to the emerging picture of<br \/>\n    how individualized neoantigen therapy may advance melanoma treatment and the<br \/>\n    promise it may hold for other types of cancer. Together with Merck, we are<br \/>\n    rapidly advancing our efforts to move this forward for patients.\u201d&nbsp;\n  <\/p>\n<p>\n    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; \u201cPatients with stage III and IV<br \/>\n    melanoma can be at high risk of having their cancer recur or metastasize to<br \/>\n    other sites,\u201d said Dr. Eric H. Rubin, senior vice president, global<br \/>\n    clinical development, Merck Research Laboratories. \u201cThese new DMFS<br \/>\n    results build upon the positive recurrence-free survival data previously<br \/>\n    observed from this Phase 2b study, and we look forward to working with Moderna<br \/>\n    to initiate a Phase 3 study in melanoma later this year.\u201d\n  <\/p>\n<p>\n    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Based on data from<br \/>\n    KEYNOTE-942\/mRNA-4157-P201, the U.S. Food and Drug Administration and European<br \/>\n    Medicines Agency granted Breakthrough Therapy Designation and the Priority<br \/>\n    Medicines (PRIME) scheme, respectively, for mRNA-4157 (V940) in combination<br \/>\n    with KEYTRUDA for the adjuvant treatment of patients with high-risk melanoma<br \/>\n    following complete resection. The companies recently announced the first<br \/>\n    presentation of the study\u2019s primary endpoint, RFS, from the Phase 2<br \/>\n    KEYNOTE-942\/mRNA-4157-P201 trial in April 2023 at the American Association for<br \/>\n    Cancer Research (AACR) Annual Meeting.\n  <\/p>\n<p>\n    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Adverse events reported with mRNA-4157<br \/>\n    (V940) in KEYNOTE-942 were consistent with those previously observed in a<br \/>\n    Phase 1 clinical trial. The safety profile of KEYTRUDA was consistent with<br \/>\n    findings from previous studies. The number of patients reporting treatment<br \/>\n    related Grade \u2265 3 adverse events were similar between the arms (25% vs 18%,<br \/>\n    respectively). The most common adverse events of any grade attributed to<br \/>\n    either mRNA-4157 (V940) or the combination of mRNA-4157 (V940) and KEYTRUDA<br \/>\n    were fatigue (60.6%), injection site pain (55.8%) and chills (50.0%).\n  <\/p>\n<p>\n    <strong>Exploratory Subgroup Analysis Evaluating Minimal Residual Disease by<br \/>\n      ctDNA<\/strong>\n  <\/p>\n<p>\n    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Data from an exploratory subgroup analysis<br \/>\n    of KEYNOTE-942\/mRNA-4157-P201 (Abstract #LBA9515) evaluating minimal residual<br \/>\n    disease (MRD) by circulating tumor DNA (ctDNA) as a biomarker of RFS in<br \/>\n    resected high-risk melanoma patients treated with mRNA-4157 (V940) in<br \/>\n    combination with KEYTRUDA were also presented. For ctDNA assessments, tumor<br \/>\n    core biopsies and matched whole-blood samples were subjected to whole-exome<br \/>\n    sequencing to identify patient-specific somatic variants. The personalized<br \/>\n    amplicon-based next-generation sequencing assay from NeoGenomics<br \/>\n    (RaDaR<sup>\u00ae<\/sup>) was used to select up to 48 variants most suitable for<br \/>\n    MRD detection and analysis of ctDNA in baseline plasma samples. The<br \/>\n    ctDNA-evaluable population (n=125) across both study arms was representative<br \/>\n    of the total ITT population (n=157). The majority of ctDNA-evaluable patients<br \/>\n    were ctDNA-negative at baseline (88.0%, n=110\/125), compared to ctDNA-positive<br \/>\n    patients at baseline (12.0%, n=15\/125). In ctDNA-negative patients at<br \/>\n    baseline, RFS was higher with mRNA-4157 (V940) in combination with KEYTRUDA<br \/>\n    (n=77) versus KEYTRUDA monotherapy (n=33), representing a 78% reduction in<br \/>\n    recurrence or death (HR=0.225 [95% CI 0.095-0.531]). A similar trend was<br \/>\n    observed for ctDNA-positive patients (n=13 for the combination arm; n=2 for<br \/>\n    KEYTRUDA only) at baseline. However, the small sample size of the ctDNA<br \/>\n    subgroups limits the interpretation of these results. The association between<br \/>\n    MRD patterns and mRNA-4157 (V940) treatment effect will be further explored in<br \/>\n    upcoming planned studies.\n  <\/p>\n<p><strong>About mRNA-4157 (V940)<\/strong><\/p>\n<p>\n    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; mRNA-4157 (V940) is a novel investigational<br \/>\n    messenger ribonucleic acid (mRNA)-based individualized neoantigen therapy<sup>1<\/sup><br \/>\n    consisting of a single synthetic mRNA coding for up to 34 neoantigens that is<br \/>\n    designed and produced based on the unique mutational signature of the DNA<br \/>\n    sequence of the patient\u2019s tumor. Upon administration into the body, the<br \/>\n    algorithmically derived and RNA-encoded neoantigen sequences are endogenously<br \/>\n    translated and undergo natural cellular antigen processing and presentation, a<br \/>\n    key step in adaptive immunity.\n  <\/p>\n<p>\n    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Individualized neoantigen therapies are<br \/>\n    designed to prime the immune system so that a patient can generate an<br \/>\n    antitumor response specific to their tumor mutation signature. mRNA-4157<br \/>\n    (V940) is designed to stimulate an immune response by generating specific T<br \/>\n    cell responses based on the unique mutational signature of a patient\u2019s<br \/>\n    tumor. KEYTRUDA is an immunotherapy that works by increasing the ability of<br \/>\n    the body\u2019s immune system to help detect and fight tumor cells. Based on<br \/>\n    early clinical studies, combining mRNA-4157 (V940) with KEYTRUDA may<br \/>\n    potentially provide an additive benefit and enhance T cell-mediated<br \/>\n    destruction of tumor cells.\n  <\/p>\n<p>\n    <strong>About KEYNOTE-942\/mRNA-4157-P201 (<\/strong><a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03897881\"><strong>NCT03897881<\/strong><\/a><strong>)<\/strong>\n  <\/p>\n<p>\n    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; KEYNOTE-942 is an ongoing randomized,<br \/>\n    open-label Phase 2b trial that enrolled 157 patients with high-risk stage<br \/>\n    III\/IV melanoma. Following complete surgical resection, patients were<br \/>\n    randomized 2:1 (stratified by stage) to receive mRNA-4157 (V940) (1 mg every<br \/>\n    three weeks for nine doses) and KEYTRUDA (200 mg every three weeks up to 18<br \/>\n    cycles [for approximately one year]) versus KEYTRUDA alone for approximately<br \/>\n    one year until disease recurrence or unacceptable toxicity. The primary<br \/>\n    endpoint is RFS, defined as the time from first dose of KEYTRUDA until the<br \/>\n    date of first recurrence (local, regional, or distant metastasis), a new<br \/>\n    primary melanoma, or death from any cause in the intention-to-treat<br \/>\n    population. Secondary endpoints include DMFS and safety, and exploratory<br \/>\n    endpoints include distribution of TMB expression in baseline tumor samples<br \/>\n    across study arms and their association with the primary RFS endpoint.\n  <\/p>\n<p>\n    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Key eligibility criteria for the trial<br \/>\n    included: patients with resectable cutaneous melanoma metastatic to a lymph<br \/>\n    node and at high risk of recurrence, patients with complete resection within<br \/>\n    13 weeks prior to the first dose of KEYTRUDA, patients were disease free at<br \/>\n    study entry (after surgery) with no loco-regional relapse or distant<br \/>\n    metastasis and no clinical evidence of brain metastases, patients had a<br \/>\n    formalin fixed paraffin embedded (FFPE) tumor sample available suitable for<br \/>\n    sequencing, Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or<br \/>\n    1 and patients with normal organ and marrow function reported at<br \/>\n    screening.&nbsp;\n  <\/p>\n<p><strong>About melanoma<\/strong><\/p>\n<p>\n    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Melanoma, the most serious form of skin<br \/>\n    cancer, is characterized by the uncontrolled growth of pigment-producing<br \/>\n    cells. The rates of melanoma have been rising over the past few decades, with<br \/>\n    nearly 325,000 new cases diagnosed worldwide in 2020. In the U.S., skin cancer<br \/>\n    is one of the most common types of cancer diagnosed, and melanoma accounts for<br \/>\n    a large majority of skin cancer deaths. It is estimated there will be nearly<br \/>\n    100,000 new cases of melanoma diagnosed and almost 8,000 deaths resulting from<br \/>\n    the disease in the U.S. in 2023. The five-year survival rates are estimated to<br \/>\n    be approximately 60.3% for stage III and 16.2% for stage IV.\n  <\/p>\n<p>\n    <strong>About KEYTRUDA<\/strong><strong><sup>\u00ae<\/sup><\/strong><strong> (pembrolizumab) injection, 100 mg<\/strong>\n  <\/p>\n<p>\n    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; KEYTRUDA is an anti-programmed death<br \/>\n    receptor-1 (PD-1) therapy that works by increasing the ability of the<br \/>\n    body\u2019s immune system to help detect and fight tumor cells. KEYTRUDA is a<br \/>\n    humanized monoclonal antibody that blocks the interaction between PD-1 and its<br \/>\n    ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect<br \/>\n    both tumor cells and healthy cells.\n  <\/p>\n<p>\n    Merck has the industry\u2019s largest immuno-oncology clinical research<br \/>\n    program. There are currently more than 1,600 trials studying KEYTRUDA across a<br \/>\n    wide variety of cancers and treatment settings. The KEYTRUDA clinical program<br \/>\n    seeks to understand the role of KEYTRUDA across cancers and the factors that<br \/>\n    may predict a patient&#8217;s likelihood of benefitting from treatment with<br \/>\n    KEYTRUDA, including exploring several different biomarkers.\n  <\/p>\n<p>\n    <strong>Selected KEYTRUDA<\/strong><strong><sup>\u00ae<\/sup><\/strong><strong> (pembrolizumab) Indications in the U.S.<\/strong>\n  <\/p>\n<p><em>Melanoma<\/em><\/p>\n<p>\n    <em>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; KEYTRUDA<\/em> is indicated for the<br \/>\n    treatment of patients with unresectable or metastatic melanoma.\n  <\/p>\n<p>\n    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; KEYTRUDA is indicated for the adjuvant<br \/>\n    treatment of adult and pediatric (12 years and older) patients with stage IIB,<br \/>\n    IIC, or III melanoma following complete resection.\n  <\/p>\n<p>\n    <em>See additional selected indications for KEYTRUDA in the U.S. after the<br \/>\n      Selected Important Safety Information<\/em>\n  <\/p>\n<p><strong>Selected Important Safety Information for KEYTRUDA<\/strong><\/p>\n<p><strong>Severe and Fatal Immune-Mediated Adverse Reactions<\/strong><\/p>\n<p>\n    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;KEYTRUDA is a monoclonal antibody<br \/>\n    that belongs to a class of drugs that bind to either the PD-1 or the PD-L1,<br \/>\n    blocking the PD-1\/PD-L1 pathway, thereby removing inhibition of the immune<br \/>\n    response, potentially breaking peripheral tolerance and inducing<br \/>\n    immune-mediated adverse reactions. Immune-mediated adverse reactions, which<br \/>\n    may be severe or fatal, can occur in any organ system or tissue, can affect<br \/>\n    more than one body system simultaneously, and can occur at any time after<br \/>\n    starting treatment or after discontinuation of treatment. Important<br \/>\n    immune-mediated adverse reactions listed here may not include all possible<br \/>\n    severe and fatal immune-mediated adverse reactions.\n  <\/p>\n<p>\n    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Monitor patients closely for symptoms<br \/>\n    and signs that may be clinical manifestations of underlying immune-mediated<br \/>\n    adverse reactions. Early identification and management are essential to ensure<br \/>\n    safe use of anti\u2013PD-1\/PD-L1 treatments. Evaluate liver enzymes,<br \/>\n    creatinine, and thyroid function at baseline and periodically during<br \/>\n    treatment. For patients with TNBC treated with KEYTRUDA in the neoadjuvant<br \/>\n    setting, monitor blood cortisol at baseline, prior to surgery, and as<br \/>\n    clinically indicated. In cases of suspected immune-mediated adverse reactions,<br \/>\n    initiate appropriate workup to exclude alternative etiologies, including<br \/>\n    infection. Institute medical management promptly, including specialty<br \/>\n    consultation as appropriate.\n  <\/p>\n<p>\n    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Withhold or permanently discontinue<br \/>\n    KEYTRUDA depending on severity of the immune-mediated adverse reaction. In<br \/>\n    general, if KEYTRUDA requires interruption or discontinuation, administer<br \/>\n    systemic corticosteroid therapy (1 to 2 mg\/kg\/day prednisone or equivalent)<br \/>\n    until improvement to Grade 1 or less. Upon improvement to Grade 1 or less,<br \/>\n    initiate corticosteroid taper and continue to taper over at least 1 month.<br \/>\n    Consider administration of other systemic immunosuppressants in patients whose<br \/>\n    adverse reactions are not controlled with corticosteroid therapy.\n  <\/p>\n<p>Immune-Mediated Pneumonitis<\/p>\n<p>\n    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; KEYTRUDA can cause immune-mediated<br \/>\n    pneumonitis. The incidence is higher in patients who have received prior<br \/>\n    thoracic radiation. Immune-mediated pneumonitis occurred in 3.4% (94\/2799) of<br \/>\n    patients receiving KEYTRUDA, including fatal (0.1%), Grade 4 (0.3%), Grade 3<br \/>\n    (0.9%), and Grade 2 (1.3%) reactions. Systemic corticosteroids were required<br \/>\n    in 67% (63\/94) of patients. Pneumonitis led to permanent discontinuation of<br \/>\n    KEYTRUDA in 1.3% (36) and withholding in 0.9% (26) of patients. All patients<br \/>\n    who were withheld reinitiated KEYTRUDA after symptom improvement; of these,<br \/>\n    23% had recurrence. Pneumonitis resolved in 59% of the 94 patients.\n  <\/p>\n<p>\n    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Pneumonitis occurred in 8% (31\/389) of<br \/>\n    adult patients with cHL receiving KEYTRUDA as a single agent, including Grades<br \/>\n    3-4 in 2.3% of patients. Patients received high-dose corticosteroids for a<br \/>\n    median duration of 10 days (range: 2 days to 53 months). Pneumonitis rates<br \/>\n    were similar in patients with and without prior thoracic radiation.<br \/>\n    Pneumonitis led to discontinuation of KEYTRUDA in 5.4% (21) of patients. Of<br \/>\n    the patients who developed pneumonitis, 42% interrupted KEYTRUDA, 68%<br \/>\n    discontinued KEYTRUDA, and 77% had resolution.\n  <\/p>\n<p>\n    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Pneumonitis occurred in 41 (7%) patients,<br \/>\n    including fatal (0.2%), Grade 4 (0.3%), and Grade 3 (1%) adverse reactions. In<br \/>\n    adult patients who received adjuvant therapy for NSCLC, patients received<br \/>\n    high-dose corticosteroids for a median duration of 10 days (range: 1 day to<br \/>\n    2.3 months). Pneumonitis led to discontinuation of KEYTRUDA in 26 (4.5%) of<br \/>\n    patients. Of the patients who developed pneumonitis, 54% interrupted KEYTRUDA,<br \/>\n    63% discontinued KEYTRUDA, and 71% had resolution.\n  <\/p>\n<p>Immune-Mediated Colitis<\/p>\n<p>\n    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; KEYTRUDA can cause immune-mediated colitis,<br \/>\n    which may present with diarrhea. Cytomegalovirus infection\/reactivation has<br \/>\n    been reported in patients with corticosteroid-refractory immune-mediated<br \/>\n    colitis. In cases of corticosteroid-refractory colitis, consider repeating<br \/>\n    infectious workup to exclude alternative etiologies. Immune-mediated colitis<br \/>\n    occurred in 1.7% (48\/2799) of patients receiving KEYTRUDA, including Grade 4<br \/>\n    (&lt;0.1%), Grade 3 (1.1%), and Grade 2 (0.4%) reactions. Systemic<br \/>\n    corticosteroids were required in 69% (33\/48); additional immunosuppressant<br \/>\n    therapy was required in 4.2% of patients. Colitis led to permanent<br \/>\n    discontinuation of KEYTRUDA in 0.5% (15) and withholding in 0.5% (13) of<br \/>\n    patients. All patients who were withheld reinitiated KEYTRUDA after symptom<br \/>\n    improvement; of these, 23% had recurrence. Colitis resolved in 85% of the 48<br \/>\n    patients.\n  <\/p>\n<p>Hepatotoxicity and Immune-Mediated Hepatitis<\/p>\n<p><em>KEYTRUDA as a Single Agent<\/em><\/p>\n<p>\n    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; KEYTRUDA can cause immune-mediated<br \/>\n    hepatitis. Immune-mediated hepatitis occurred in 0.7% (19\/2799) of patients<br \/>\n    receiving KEYTRUDA, including Grade 4 (&lt;0.1%), Grade 3 (0.4%), and Grade 2<br \/>\n    (0.1%) reactions. Systemic corticosteroids were required in 68% (13\/19) of<br \/>\n    patients; additional immunosuppressant therapy was required in 11% of<br \/>\n    patients. Hepatitis led to permanent discontinuation of KEYTRUDA in 0.2% (6)<br \/>\n    and withholding in 0.3% (9) of patients. All patients who were withheld<br \/>\n    reinitiated KEYTRUDA after symptom improvement; of these, none had recurrence.<br \/>\n    Hepatitis resolved in 79% of the 19 patients.\n  <\/p>\n<p><em>KEYTRUDA With Axitinib<\/em><\/p>\n<p>\n    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; KEYTRUDA in combination with axitinib can<br \/>\n    cause hepatic toxicity. Monitor liver enzymes before initiation of and<br \/>\n    periodically throughout treatment. Consider monitoring more frequently as<br \/>\n    compared to when the drugs are administered as single agents. For elevated<br \/>\n    liver enzymes, interrupt KEYTRUDA and axitinib, and consider administering<br \/>\n    corticosteroids as needed. With the combination of KEYTRUDA and axitinib,<br \/>\n    Grades 3 and 4 increased alanine aminotransferase (ALT) (20%) and increased<br \/>\n    aspartate aminotransferase (AST) (13%) were seen at a higher frequency<br \/>\n    compared to KEYTRUDA alone. Fifty-nine percent of the patients with increased<br \/>\n    ALT received systemic corticosteroids. In patients with ALT \u22653 times upper<br \/>\n    limit of normal (ULN) (Grades 2-4, n=116), ALT resolved to Grades 0-1 in 94%.<br \/>\n    Among the 92 patients who were rechallenged with either KEYTRUDA (n=3) or<br \/>\n    axitinib (n=34) administered as a single agent or with both (n=55), recurrence<br \/>\n    of ALT \u22653 times ULN was observed in 1 patient receiving KEYTRUDA, 16<br \/>\n    patients receiving axitinib, and 24 patients receiving both. All patients with<br \/>\n    a recurrence of ALT \u22653 ULN subsequently recovered from the event.\n  <\/p>\n<p>Immune-Mediated Endocrinopathies<\/p>\n<p><em>Adrenal Insufficiency<\/em><\/p>\n<p>\n    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; KEYTRUDA can cause primary or secondary<br \/>\n    adrenal insufficiency. For Grade 2 or higher, initiate symptomatic treatment,<br \/>\n    including hormone replacement as clinically indicated. Withhold KEYTRUDA<br \/>\n    depending on severity. Adrenal insufficiency occurred in 0.8% (22\/2799) of<br \/>\n    patients receiving KEYTRUDA, including Grade 4 (&lt;0.1%), Grade 3 (0.3%), and<br \/>\n    Grade 2 (0.3%) reactions. Systemic corticosteroids were required in 77%<br \/>\n    (17\/22) of patients; of these, the majority remained on systemic<br \/>\n    corticosteroids. Adrenal insufficiency led to permanent discontinuation of<br \/>\n    KEYTRUDA in &lt;0.1% (1) and withholding in 0.3% (8) of patients. All patients<br \/>\n    who were withheld reinitiated KEYTRUDA after symptom improvement.\n  <\/p>\n<p><em>Hypophysitis<\/em><\/p>\n<p>\n    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; KEYTRUDA can cause immune-mediated<br \/>\n    hypophysitis. Hypophysitis can present with acute symptoms associated with<br \/>\n    mass effect such as headache, photophobia, or visual field defects.<br \/>\n    Hypophysitis can cause hypopituitarism. Initiate hormone replacement as<br \/>\n    indicated. Withhold or permanently discontinue KEYTRUDA depending on severity.<br \/>\n    Hypophysitis occurred in 0.6% (17\/2799) of patients receiving KEYTRUDA,<br \/>\n    including Grade 4 (&lt;0.1%), Grade 3 (0.3%), and Grade 2 (0.2%) reactions.<br \/>\n    Systemic corticosteroids were required in 94% (16\/17) of patients; of these,<br \/>\n    the majority remained on systemic corticosteroids. Hypophysitis led to<br \/>\n    permanent discontinuation of KEYTRUDA in 0.1% (4) and withholding in 0.3% (7)<br \/>\n    of patients. All patients who were withheld reinitiated KEYTRUDA after symptom<br \/>\n    improvement.\n  <\/p>\n<p><em>Thyroid Disorders<\/em><\/p>\n<p>\n    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; KEYTRUDA can cause immune-mediated thyroid<br \/>\n    disorders. Thyroiditis can present with or without endocrinopathy.<br \/>\n    Hypothyroidism can follow hyperthyroidism. Initiate hormone replacement for<br \/>\n    hypothyroidism or institute medical management of hyperthyroidism as<br \/>\n    clinically indicated. Withhold or permanently discontinue KEYTRUDA depending<br \/>\n    on severity. Thyroiditis occurred in 0.6% (16\/2799) of patients receiving<br \/>\n    KEYTRUDA, including Grade 2 (0.3%). None discontinued, but KEYTRUDA was<br \/>\n    withheld in &lt;0.1% (1) of patients.\n  <\/p>\n<p>\n    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Hyperthyroidism occurred in 3.4% (96\/2799)<br \/>\n    of patients receiving KEYTRUDA, including Grade 3 (0.1%) and Grade 2 (0.8%).<br \/>\n    It led to permanent discontinuation of KEYTRUDA in &lt;0.1% (2) and<br \/>\n    withholding in 0.3% (7) of patients. All patients who were withheld<br \/>\n    reinitiated KEYTRUDA after symptom improvement. Hypothyroidism occurred in 8%<br \/>\n    (237\/2799) of patients receiving KEYTRUDA, including Grade 3 (0.1%) and Grade<br \/>\n    2 (6.2%). It led to permanent discontinuation of KEYTRUDA in &lt;0.1% (1) and<br \/>\n    withholding in 0.5% (14) of patients. All patients who were withheld<br \/>\n    reinitiated KEYTRUDA after symptom improvement. The majority of patients with<br \/>\n    hypothyroidism required long-term thyroid hormone replacement. The incidence<br \/>\n    of new or worsening hypothyroidism was higher in 1185 patients with HNSCC,<br \/>\n    occurring in 16% of patients receiving KEYTRUDA as a single agent or in<br \/>\n    combination with platinum and FU, including Grade 3 (0.3%) hypothyroidism. The<br \/>\n    incidence of new or worsening hypothyroidism was higher in 389 adult patients<br \/>\n    with cHL (17%) receiving KEYTRUDA as a single agent, including Grade 1 (6.2%)<br \/>\n    and Grade 2 (10.8%) hypothyroidism. The incidence of new or worsening<br \/>\n    hyperthyroidism was higher in 580 patients with resected NSCLC, occurring in<br \/>\n    11% of patients receiving KEYTRUDA as a single agent as adjuvant treatment,<br \/>\n    including Grade 3 (0.2%) hyperthyroidism. The incidence of new or worsening<br \/>\n    hypothyroidism was higher in 580 patients with resected NSCLC, occurring in<br \/>\n    22% of patients receiving KEYTRUDA as a single agent as adjuvant treatment<br \/>\n    (KEYNOTE-091), including Grade 3 (0.3%) hypothyroidism.\n  <\/p>\n<p>\n    <em>Type 1 Diabetes Mellitus (DM), Which Can Present With Diabetic<br \/>\n      Ketoacidosis<\/em>\n  <\/p>\n<p>\n    Monitor patients for hyperglycemia or other signs and symptoms of diabetes.<br \/>\n    Initiate treatment with insulin as clinically indicated. Withhold KEYTRUDA<br \/>\n    depending on severity. Type 1 DM occurred in 0.2% (6\/2799) of patients<br \/>\n    receiving KEYTRUDA. It led to permanent discontinuation in &lt;0.1% (1) and<br \/>\n    withholding of KEYTRUDA in &lt;0.1% (1) of patients. All patients who were<br \/>\n    withheld reinitiated KEYTRUDA after symptom improvement.\n  <\/p>\n<p>Immune-Mediated Nephritis With Renal Dysfunction<\/p>\n<p>\n    KEYTRUDA can cause immune-mediated nephritis. Immune-mediated nephritis<br \/>\n    occurred in 0.3% (9\/2799) of patients receiving KEYTRUDA, including Grade 4<br \/>\n    (&lt;0.1%), Grade 3 (0.1%), and Grade 2 (0.1%) reactions. Systemic<br \/>\n    corticosteroids were required in 89% (8\/9) of patients. Nephritis led to<br \/>\n    permanent discontinuation of KEYTRUDA in 0.1% (3) and withholding in 0.1% (3)<br \/>\n    of patients. All patients who were withheld reinitiated KEYTRUDA after symptom<br \/>\n    improvement; of these, none had recurrence. Nephritis resolved in 56% of the 9<br \/>\n    patients.\n  <\/p>\n<p>Immune-Mediated Dermatologic Adverse Reactions<\/p>\n<p>\n    KEYTRUDA can cause immune-mediated rash or dermatitis. Exfoliative dermatitis,<br \/>\n    including Stevens-Johnson syndrome, drug rash with eosinophilia and systemic<br \/>\n    symptoms, and toxic epidermal necrolysis, has occurred with<br \/>\n    anti\u2013PD-1\/PD-L1 treatments. Topical emollients and\/or topical<br \/>\n    corticosteroids may be adequate to treat mild to moderate nonexfoliative<br \/>\n    rashes. Withhold or permanently discontinue KEYTRUDA depending on severity.<br \/>\n    Immune-mediated dermatologic adverse reactions occurred in 1.4% (38\/2799) of<br \/>\n    patients receiving KEYTRUDA, including Grade 3 (1%) and Grade 2 (0.1%)<br \/>\n    reactions. Systemic corticosteroids were required in 40% (15\/38) of patients.<br \/>\n    These reactions led to permanent discontinuation in 0.1% (2) and withholding<br \/>\n    of KEYTRUDA in 0.6% (16) of patients. All patients who were withheld<br \/>\n    reinitiated KEYTRUDA after symptom improvement; of these, 6% had recurrence.<br \/>\n    The reactions resolved in 79% of the 38 patients.\n  <\/p>\n<p>Other Immune-Mediated Adverse Reactions<\/p>\n<p>\n    The following clinically significant immune-mediated adverse reactions<br \/>\n    occurred at an incidence of &lt;1% (unless otherwise noted) in patients who<br \/>\n    received KEYTRUDA or were reported with the use of other anti\u2013PD-1\/PD-L1<br \/>\n    treatments. Severe or fatal cases have been reported for some of these adverse<br \/>\n    reactions. <em>Cardiac\/Vascular:<\/em> Myocarditis, pericarditis, vasculitis;<br \/>\n    <em>Nervous System:<\/em> Meningitis, encephalitis, myelitis and demyelination,<br \/>\n    myasthenic syndrome\/myasthenia gravis (including exacerbation),<br \/>\n    Guillain-Barr\u00e9 syndrome, nerve paresis, autoimmune neuropathy;<br \/>\n    <em>Ocular:<\/em> Uveitis, iritis and other ocular inflammatory toxicities can<br \/>\n    occur. Some cases can be associated with retinal detachment. Various grades of<br \/>\n    visual impairment, including blindness, can occur. If uveitis occurs in<br \/>\n    combination with other immune-mediated adverse reactions, consider a<br \/>\n    Vogt-Koyanagi-Harada-like syndrome, as this may require treatment with<br \/>\n    systemic steroids to reduce the risk of permanent vision loss;<br \/>\n    <em>Gastrointestinal:<\/em> Pancreatitis, to include increases in serum amylase<br \/>\n    and lipase levels, gastritis, duodenitis;<br \/>\n    <em>Musculoskeletal and Connective Tissue:<\/em> Myositis\/polymyositis,<br \/>\n    rhabdomyolysis (and associated sequelae, including renal failure), arthritis<br \/>\n    (1.5%), polymyalgia rheumatica; <em>Endocrine:<\/em> Hypoparathyroidism;<br \/>\n    <em>Hematologic\/Immune:<\/em> Hemolytic anemia, aplastic anemia, hemophagocytic<br \/>\n    lymphohistiocytosis, systemic inflammatory response syndrome, histiocytic<br \/>\n    necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune<br \/>\n    thrombocytopenic purpura, solid organ transplant rejection.\n  <\/p>\n<p><strong>Infusion-Related Reactions<\/strong><\/p>\n<p>\n    KEYTRUDA can cause severe or life-threatening infusion-related reactions,<br \/>\n    including hypersensitivity and anaphylaxis, which have been reported in 0.2%<br \/>\n    of 2799 patients receiving KEYTRUDA. Monitor for signs and symptoms of<br \/>\n    infusion-related reactions. Interrupt or slow the rate of infusion for Grade 1<br \/>\n    or Grade 2 reactions. For Grade 3 or Grade 4 reactions, stop infusion and<br \/>\n    permanently discontinue KEYTRUDA.\n  <\/p>\n<p>\n    <strong>Complications of Allogeneic Hematopoietic Stem Cell Transplantation<br \/>\n      (HSCT)<\/strong>\n  <\/p>\n<p>\n    Fatal and other serious complications can occur in patients who receive<br \/>\n    allogeneic HSCT before or after anti\u2013PD-1\/PD-L1 treatments.<br \/>\n    Transplant-related complications include hyperacute graft-versus-host disease<br \/>\n    (GVHD), acute and chronic GVHD, hepatic veno-occlusive disease after reduced<br \/>\n    intensity conditioning, and steroid-requiring febrile syndrome (without an<br \/>\n    identified infectious cause). These complications may occur despite<br \/>\n    intervening therapy between anti\u2013PD-1\/PD-L1 treatment and allogeneic<br \/>\n    HSCT. Follow patients closely for evidence of these complications and<br \/>\n    intervene promptly. Consider the benefit vs risks of using<br \/>\n    anti\u2013PD-1\/PD-L1 treatments prior to or after an allogeneic HSCT.\n  <\/p>\n<p><strong>Increased Mortality in Patients With Multiple Myeloma<\/strong><\/p>\n<p>\n    In trials in patients with multiple myeloma, the addition of KEYTRUDA to a<br \/>\n    thalidomide analogue plus dexamethasone resulted in increased mortality.<br \/>\n    Treatment of these patients with an anti\u2013PD-1\/PD-L1 treatment in this<br \/>\n    combination is not recommended outside of controlled trials.\n  <\/p>\n<p><strong>Embryofetal Toxicity<\/strong><\/p>\n<p>\n    Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n    administered to a pregnant woman. Advise women of this potential risk. In<br \/>\n    females of reproductive potential, verify pregnancy status prior to initiating<br \/>\n    KEYTRUDA and advise them to use effective contraception during treatment and<br \/>\n    for 4 months after the last dose.\n  <\/p>\n<p><strong>Adverse Reactions<\/strong><\/p>\n<p>\n    In KEYNOTE-006, KEYTRUDA was discontinued due to adverse reactions in 9% of<br \/>\n    555 patients with advanced melanoma; adverse reactions leading to permanent<br \/>\n    discontinuation in more than one patient were colitis (1.4%), autoimmune<br \/>\n    hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy (0.4%), and cardiac<br \/>\n    failure (0.4%). The most common adverse reactions (\u226520%) with KEYTRUDA were<br \/>\n    fatigue (28%), diarrhea (26%), rash (24%), and nausea (21%).\n  <\/p>\n<p>\n    In KEYNOTE-054, when KEYTRUDA was administered as a single agent to patients<br \/>\n    with stage III melanoma, KEYTRUDA was permanently discontinued due to adverse<br \/>\n    reactions in 14% of 509 patients; the most common (\u22651%) were pneumonitis<br \/>\n    (1.4%), colitis (1.2%), and diarrhea (1%). Serious adverse reactions occurred<br \/>\n    in 25% of patients receiving KEYTRUDA. The most common adverse reaction<br \/>\n    (\u226520%) with KEYTRUDA was diarrhea (28%). In KEYNOTE-716, when KEYTRUDA was<br \/>\n    administered as a single agent to patients with stage IIB or IIC melanoma,<br \/>\n    adverse reactions occurring in patients with stage IIB or IIC melanoma were<br \/>\n    similar to those occurring in 1011 patients with stage III melanoma from<br \/>\n    KEYNOTE-054.\n  <\/p>\n<p>\n    In KEYNOTE-189, when KEYTRUDA was administered with pemetrexed and platinum<br \/>\n    chemotherapy in metastatic nonsquamous NSCLC, KEYTRUDA was discontinued due to<br \/>\n    adverse reactions in 20% of 405 patients. The most common adverse reactions<br \/>\n    resulting in permanent discontinuation of KEYTRUDA were pneumonitis (3%) and<br \/>\n    acute kidney injury (2%). The most common adverse reactions (\u226520%) with<br \/>\n    KEYTRUDA were nausea (56%), fatigue (56%), constipation (35%), diarrhea (31%),<br \/>\n    decreased appetite (28%), rash (25%), vomiting (24%), cough (21%), dyspnea<br \/>\n    (21%), and pyrexia (20%).\n  <\/p>\n<p>\n    In KEYNOTE-407, when KEYTRUDA was administered with carboplatin and either<br \/>\n    paclitaxel or paclitaxel protein-bound in metastatic squamous NSCLC, KEYTRUDA<br \/>\n    was discontinued due to adverse reactions in 15% of 101 patients. The most<br \/>\n    frequent serious adverse reactions reported in at least 2% of patients were<br \/>\n    febrile neutropenia, pneumonia, and urinary tract infection. Adverse reactions<br \/>\n    observed in KEYNOTE-407 were similar to those observed in KEYNOTE-189 with the<br \/>\n    exception that increased incidences of alopecia (47% vs 36%) and peripheral<br \/>\n    neuropathy (31% vs 25%) were observed in the KEYTRUDA and chemotherapy arm<br \/>\n    compared to the placebo and chemotherapy arm in KEYNOTE-407.\n  <\/p>\n<p>\n    In KEYNOTE-042, KEYTRUDA was discontinued due to adverse reactions in 19% of<br \/>\n    636 patients with advanced NSCLC; the most common were pneumonitis (3%), death<br \/>\n    due to unknown cause (1.6%), and pneumonia (1.4%). The most frequent serious<br \/>\n    adverse reactions reported in at least 2% of patients were pneumonia (7%),<br \/>\n    pneumonitis (3.9%), pulmonary embolism (2.4%), and pleural effusion (2.2%).<br \/>\n    The most common adverse reaction (\u226520%) was fatigue (25%).\n  <\/p>\n<p>\n    In KEYNOTE-010, KEYTRUDA monotherapy was discontinued due to adverse reactions<br \/>\n    in 8% of 682 patients with metastatic NSCLC; the most common was pneumonitis<br \/>\n    (1.8%). The most common adverse reactions (\u226520%) were decreased appetite<br \/>\n    (25%), fatigue (25%), dyspnea (23%), and nausea (20%).\n  <\/p>\n<p>\n    Adverse reactions observed in KEYNOTE-091 were generally similar to those<br \/>\n    occurring in other patients with NSCLC receiving KEYTRUDA as a single agent,<br \/>\n    with the exception of hypothyroidism (22%), hyperthyroidism (11%), and<br \/>\n    pneumonitis (7%). Two fatal reactions of myocarditis occurred.\n  <\/p>\n<p>\n    In KEYNOTE-048, KEYTRUDA monotherapy was discontinued due to adverse events in<br \/>\n    12% of 300 patients with HNSCC; the most common adverse reactions leading to<br \/>\n    permanent discontinuation were sepsis (1.7%) and pneumonia (1.3%). The most<br \/>\n    common adverse reactions (\u226520%) were fatigue (33%), constipation (20%), and<br \/>\n    rash (20%).\n  <\/p>\n<p>\n    In KEYNOTE-048, when KEYTRUDA was administered in combination with platinum<br \/>\n    (cisplatin or carboplatin) and FU chemotherapy, KEYTRUDA was discontinued due<br \/>\n    to adverse reactions in 16% of 276 patients with HNSCC. The most common<br \/>\n    adverse reactions resulting in permanent discontinuation of KEYTRUDA were<br \/>\n    pneumonia (2.5%), pneumonitis (1.8%), and septic shock (1.4%). The most common<br \/>\n    adverse reactions (\u226520%) were nausea (51%), fatigue (49%), constipation<br \/>\n    (37%), vomiting (32%), mucosal inflammation (31%), diarrhea (29%), decreased<br \/>\n    appetite (29%), stomatitis (26%), and cough (22%).\n  <\/p>\n<p>\n    In KEYNOTE-012, KEYTRUDA was discontinued due to adverse reactions in 17% of<br \/>\n    192 patients with HNSCC. Serious adverse reactions occurred in 45% of<br \/>\n    patients. The most frequent serious adverse reactions reported in at least 2%<br \/>\n    of patients were pneumonia, dyspnea, confusional state, vomiting, pleural<br \/>\n    effusion, and respiratory failure. The most common adverse reactions (\u226520%)<br \/>\n    were fatigue, decreased appetite, and dyspnea. Adverse reactions occurring in<br \/>\n    patients with HNSCC were generally similar to those occurring in patients with<br \/>\n    melanoma or NSCLC who received KEYTRUDA as a monotherapy, with the exception<br \/>\n    of increased incidences of facial edema and new or worsening hypothyroidism.\n  <\/p>\n<p>\n    In KEYNOTE-204, KEYTRUDA was discontinued due to adverse reactions in 14% of<br \/>\n    148 patients with cHL. Serious adverse reactions occurred in 30% of patients<br \/>\n    receiving KEYTRUDA; those \u22651% were pneumonitis, pneumonia, pyrexia,<br \/>\n    myocarditis, acute kidney injury, febrile neutropenia, and sepsis. Three<br \/>\n    patients died from causes other than disease progression: 2 from complications<br \/>\n    after allogeneic HSCT and 1 from unknown cause. The most common adverse<br \/>\n    reactions (\u226520%) were upper respiratory tract infection (41%),<br \/>\n    musculoskeletal pain (32%), diarrhea (22%), and pyrexia, fatigue, rash, and<br \/>\n    cough (20% each).\n  <\/p>\n<p>\n    In KEYNOTE-087, KEYTRUDA was discontinued due to adverse reactions in 5% of<br \/>\n    210 patients with cHL. Serious adverse reactions occurred in 16% of patients;<br \/>\n    those \u22651% were pneumonia, pneumonitis, pyrexia, dyspnea, GVHD, and herpes<br \/>\n    zoster. Two patients died from causes other than disease progression: 1 from<br \/>\n    GVHD after subsequent allogeneic HSCT and 1 from septic shock. The most common<br \/>\n    adverse reactions (\u226520%) were fatigue (26%), pyrexia (24%), cough (24%),<br \/>\n    musculoskeletal pain (21%), diarrhea (20%), and rash (20%).\n  <\/p>\n<p>\n    In KEYNOTE-170, KEYTRUDA was discontinued due to adverse reactions in 8% of 53<br \/>\n    patients with PMBCL. Serious adverse reactions occurred in 26% of patients and<br \/>\n    included arrhythmia (4%), cardiac tamponade (2%), myocardial infarction (2%),<br \/>\n    pericardial effusion (2%), and pericarditis (2%). Six (11%) patients died<br \/>\n    within 30 days of start of treatment. The most common adverse reactions<br \/>\n    (\u226520%) were musculoskeletal pain (30%), upper respiratory tract infection<br \/>\n    and pyrexia (28% each), cough (26%), fatigue (23%), and dyspnea (21%).\n  <\/p>\n<p>\n    In KEYNOTE-869, when KEYTRUDA was administered in combination with enfortumab<br \/>\n    vedotin to patients with locally advanced or mUC and who are not eligible for<br \/>\n    cisplatin-based chemotherapy (n=121), fatal adverse reactions occurred in 5%<br \/>\n    of patients, including sepsis (1.6%), bullous dermatitis (0.8%), myasthenia<br \/>\n    gravis (0.8%), and pneumonitis (0.8%). Serious adverse reactions occurred in<br \/>\n    50% of patients receiving KEYTRUDA in combination with enfortumab vedotin; the<br \/>\n    serious adverse reactions in \u22652% of patients were acute kidney injury (7%),<br \/>\n    urinary tract infection (7%), urosepsis (5%), hematuria (3.3%), pneumonia<br \/>\n    (3.3%), pneumonitis (3.3%), sepsis (3.3%), anemia (2.5%), diarrhea (2.5%),<br \/>\n    hypotension (2.5%), myasthenia gravis (2.5%), myositis (2.5%), and urinary<br \/>\n    retention (2.5%). Permanent discontinuation of KEYTRUDA occurred in 32% of<br \/>\n    patients. The most common adverse reactions (\u22652%) resulting in permanent<br \/>\n    discontinuation of KEYTRUDA were pneumonitis (5%), peripheral neuropathy (5%),<br \/>\n    rash (3.3%), and myasthenia gravis (2.5%). The most common adverse reactions<br \/>\n    (\u226520%) occurring in patients treated with KEYTRUDA in combination with<br \/>\n    enfortumab vedotin were rash (71%), peripheral neuropathy (65%), fatigue<br \/>\n    (60%), alopecia (52%), weight loss (48%), diarrhea (45%), pruritus (40%),<br \/>\n    decreased appetite (38%), nausea (36%), dysgeusia (35%), urinary tract<br \/>\n    infection (30%), constipation (27%), peripheral edema (26%), dry eye (25%),<br \/>\n    dizziness (23%), arthralgia (23%), and dry skin (21%).\n  <\/p>\n<p>\n    In KEYNOTE-052, KEYTRUDA was discontinued due to adverse reactions in 11% of<br \/>\n    370 patients with locally advanced or mUC. Serious adverse reactions occurred<br \/>\n    in 42% of patients; those \u22652% were urinary tract infection, hematuria,<br \/>\n    acute kidney injury, pneumonia, and urosepsis. The most common adverse<br \/>\n    reactions (\u226520%) were fatigue (38%), musculoskeletal pain (24%), decreased<br \/>\n    appetite (22%), constipation (21%), rash (21%), and diarrhea (20%).\n  <\/p>\n<p>\n    In KEYNOTE-045, KEYTRUDA was discontinued due to adverse reactions in 8% of<br \/>\n    266 patients with locally advanced or mUC. The most common adverse reaction<br \/>\n    resulting in permanent discontinuation of KEYTRUDA was pneumonitis (1.9%).<br \/>\n    Serious adverse reactions occurred in 39% of KEYTRUDA-treated patients; those<br \/>\n    \u22652% were urinary tract infection, pneumonia, anemia, and pneumonitis. The<br \/>\n    most common adverse reactions (\u226520%) in patients who received KEYTRUDA were<br \/>\n    fatigue (38%), musculoskeletal pain (32%), pruritus (23%), decreased appetite<br \/>\n    (21%), nausea (21%), and rash (20%).\n  <\/p>\n<p>\n    In KEYNOTE-057, KEYTRUDA was discontinued due to adverse reactions in 11% of<br \/>\n    148 patients with high-risk NMIBC. The most common adverse reaction resulting<br \/>\n    in permanent discontinuation of KEYTRUDA was pneumonitis (1.4%). Serious<br \/>\n    adverse reactions occurred in 28% of patients; those \u22652% were pneumonia<br \/>\n    (3%), cardiac ischemia (2%), colitis (2%), pulmonary embolism (2%), sepsis<br \/>\n    (2%), and urinary tract infection (2%). The most common adverse reactions<br \/>\n    (\u226520%) were fatigue (29%), diarrhea (24%), and rash (24%).\n  <\/p>\n<p>\n    Adverse reactions occurring in patients with MSI-H or dMMR CRC were similar to<br \/>\n    those occurring in patients with melanoma or NSCLC who received KEYTRUDA as a<br \/>\n    monotherapy.\n  <\/p>\n<p>\n    In KEYNOTE-158 and KEYNOTE-164, adverse reactions occurring in patients with<br \/>\n    MSI-H or dMMR cancer were similar to those occurring in patients with other<br \/>\n    solid tumors who received KEYTRUDA as a single agent.\n  <\/p>\n<p>\n    In KEYNOTE-811, when KEYTRUDA was administered in combination with<br \/>\n    trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, KEYTRUDA<br \/>\n    was discontinued due to adverse reactions in 6% of 217 patients with locally<br \/>\n    advanced unresectable or metastatic HER2+ gastric or GEJ adenocarcinoma. The<br \/>\n    most common adverse reaction resulting in permanent discontinuation was<br \/>\n    pneumonitis (1.4%). In the KEYTRUDA arm versus placebo, there was a difference<br \/>\n    of \u22655% incidence between patients treated with KEYTRUDA versus standard of<br \/>\n    care for diarrhea (53% vs 44%) and nausea (49% vs 44%).\n  <\/p>\n<p>\n    The most common adverse reactions (reported in \u226520%) in patients receiving<br \/>\n    KEYTRUDA in combination with chemotherapy were fatigue\/asthenia, nausea,<br \/>\n    constipation, diarrhea, decreased appetite, rash, vomiting, cough, dyspnea,<br \/>\n    pyrexia, alopecia, peripheral neuropathy, mucosal inflammation, stomatitis,<br \/>\n    headache, weight loss, abdominal pain, arthralgia, myalgia, and insomnia.\n  <\/p>\n<p>\n    In KEYNOTE-590, when KEYTRUDA was administered with cisplatin and fluorouracil<br \/>\n    to patients with metastatic or locally advanced esophageal or GEJ (tumors with<br \/>\n    epicenter 1 to 5 centimeters above the GEJ) carcinoma who were not candidates<br \/>\n    for surgical resection or definitive chemoradiation, KEYTRUDA was discontinued<br \/>\n    due to adverse reactions in 15% of 370 patients. The most common adverse<br \/>\n    reactions resulting in permanent discontinuation of KEYTRUDA (\u22651%) were<br \/>\n    pneumonitis (1.6%), acute kidney injury (1.1%), and pneumonia (1.1%). The most<br \/>\n    common adverse reactions (\u226520%) with KEYTRUDA in combination with<br \/>\n    chemotherapy were nausea (67%), fatigue (57%), decreased appetite (44%),<br \/>\n    constipation (40%), diarrhea (36%), vomiting (34%), stomatitis (27%), and<br \/>\n    weight loss (24%).\n  <\/p>\n<p>\n    Adverse reactions occurring in patients with esophageal cancer who received<br \/>\n    KEYTRUDA as a monotherapy were similar to those occurring in patients with<br \/>\n    melanoma or NSCLC who received KEYTRUDA as a monotherapy.\n  <\/p>\n<p>\n    In KEYNOTE-826, when KEYTRUDA was administered in combination with paclitaxel<br \/>\n    and cisplatin or paclitaxel and carboplatin, with or without bevacizumab<br \/>\n    (n=307), to patients with persistent, recurrent, or first-line metastatic<br \/>\n    cervical cancer regardless of tumor PD-L1 expression who had not been treated<br \/>\n    with chemotherapy except when used concurrently as a radio-sensitizing agent,<br \/>\n    fatal adverse reactions occurred in 4.6% of patients, including 3 cases of<br \/>\n    hemorrhage, 2 cases each of sepsis and due to unknown causes, and 1 case each<br \/>\n    of acute myocardial infarction, autoimmune encephalitis, cardiac arrest,<br \/>\n    cerebrovascular accident, femur fracture with perioperative pulmonary embolus,<br \/>\n    intestinal perforation, and pelvic infection. Serious adverse reactions<br \/>\n    occurred in 50% of patients receiving KEYTRUDA in combination with<br \/>\n    chemotherapy with or without bevacizumab; those \u22653% were febrile<br \/>\n    neutropenia (6.8%), urinary tract infection (5.2%), anemia (4.6%), and acute<br \/>\n    kidney injury and sepsis (3.3% each).\n  <\/p>\n<p>\n    KEYTRUDA was discontinued in 15% of patients due to adverse reactions. The<br \/>\n    most common adverse reaction resulting in permanent discontinuation (\u22651%)<br \/>\n    was colitis (1%).\n  <\/p>\n<p>\n    For patients treated with KEYTRUDA, chemotherapy, and bevacizumab (n=196), the<br \/>\n    most common adverse reactions (\u226520%) were peripheral neuropathy (62%),<br \/>\n    alopecia (58%), anemia (55%), fatigue\/asthenia (53%), nausea and neutropenia<br \/>\n    (41% each), diarrhea (39%), hypertension and thrombocytopenia (35% each),<br \/>\n    constipation and arthralgia (31% each), vomiting (30%), urinary tract<br \/>\n    infection (27%), rash (26%), leukopenia (24%), hypothyroidism (22%), and<br \/>\n    decreased appetite (21%).\n  <\/p>\n<p>\n    For patients treated with KEYTRUDA in combination with chemotherapy with or<br \/>\n    without bevacizumab, the most common adverse reactions (\u226520%) were<br \/>\n    peripheral neuropathy (58%), alopecia (56%), fatigue (47%), nausea (40%),<br \/>\n    diarrhea (36%), constipation (28%), arthralgia (27%), vomiting (26%),<br \/>\n    hypertension and urinary tract infection (24% each), and rash (22%).\n  <\/p>\n<p>\n    In KEYNOTE-158, KEYTRUDA was discontinued due to adverse reactions in 8% of 98<br \/>\n    patients with previously treated recurrent or metastatic cervical cancer.<br \/>\n    Serious adverse reactions occurred in 39% of patients receiving KEYTRUDA; the<br \/>\n    most frequent included anemia (7%), fistula, hemorrhage, and infections<br \/>\n    [except urinary tract infections] (4.1% each). The most common adverse<br \/>\n    reactions (\u226520%) were fatigue (43%), musculoskeletal pain (27%), diarrhea<br \/>\n    (23%), pain and abdominal pain (22% each), and decreased appetite (21%).\n  <\/p>\n<p>\n    Adverse reactions occurring in patients with HCC were generally similar to<br \/>\n    those in patients with melanoma or NSCLC who received KEYTRUDA as a<br \/>\n    monotherapy, with the exception of increased incidences of ascites (8% Grades<br \/>\n    3-4) and immune-mediated hepatitis (2.9%). Laboratory abnormalities (Grades<br \/>\n    3-4) that occurred at a higher incidence were elevated AST (20%), ALT (9%),<br \/>\n    and hyperbilirubinemia (10%).\n  <\/p>\n<p>\n    Among the 50 patients with MCC enrolled in study KEYNOTE-017, adverse<br \/>\n    reactions occurring in patients with MCC were generally similar to those<br \/>\n    occurring in patients with melanoma or NSCLC who received KEYTRUDA as a<br \/>\n    monotherapy. Laboratory abnormalities (Grades 3-4) that occurred at a higher<br \/>\n    incidence were elevated AST (11%) and hyperglycemia (19%).\n  <\/p>\n<p>\n    In KEYNOTE-426, when KEYTRUDA was administered in combination with axitinib,<br \/>\n    fatal adverse reactions occurred in 3.3% of 429 patients. Serious adverse<br \/>\n    reactions occurred in 40% of patients, the most frequent (\u22651%) were<br \/>\n    hepatotoxicity (7%), diarrhea (4.2%), acute kidney injury (2.3%), dehydration<br \/>\n    (1%), and pneumonitis (1%). Permanent discontinuation due to an adverse<br \/>\n    reaction occurred in 31% of patients; KEYTRUDA only (13%), axitinib only<br \/>\n    (13%), and the combination (8%); the most common were hepatotoxicity (13%),<br \/>\n    diarrhea\/colitis (1.9%), acute kidney injury (1.6%), and cerebrovascular<br \/>\n    accident (1.2%). The most common adverse reactions (\u226520%) were diarrhea<br \/>\n    (56%), fatigue\/asthenia (52%), hypertension (48%), hepatotoxicity (39%),<br \/>\n    hypothyroidism (35%), decreased appetite (30%), palmar-plantar<br \/>\n    erythrodysesthesia (28%), nausea (28%), stomatitis\/mucosal inflammation (27%),<br \/>\n    dysphonia (25%), rash (25%), cough (21%), and constipation (21%).\n  <\/p>\n<p>\n    In KEYNOTE-564, when KEYTRUDA was administered as a single agent for the<br \/>\n    adjuvant treatment of renal cell carcinoma, serious adverse reactions occurred<br \/>\n    in 20% of patients receiving KEYTRUDA; the serious adverse reactions (\u22651%)<br \/>\n    were acute kidney injury, adrenal insufficiency, pneumonia, colitis, and<br \/>\n    diabetic ketoacidosis (1% each). Fatal adverse reactions occurred in 0.2%<br \/>\n    including 1 case of pneumonia. Discontinuation of KEYTRUDA due to adverse<br \/>\n    reactions occurred in 21% of 488 patients; the most common (\u22651%) were<br \/>\n    increased ALT (1.6%), colitis (1%), and adrenal insufficiency (1%). The most<br \/>\n    common adverse reactions (\u226520%) were musculoskeletal pain (41%), fatigue<br \/>\n    (40%), rash (30%), diarrhea (27%), pruritus (23%), and hypothyroidism (21%).\n  <\/p>\n<p>\n    Adverse reactions occurring in patients with MSI-H or dMMR endometrial<br \/>\n    carcinoma who received KEYTRUDA as a single agent were similar to those<br \/>\n    occurring in patients with melanoma or NSCLC who received KEYTRUDA as a single<br \/>\n    agent.\n  <\/p>\n<p>\n    Adverse reactions occurring in patients with TMB-H cancer were similar to<br \/>\n    those occurring in patients with other solid tumors who received KEYTRUDA as a<br \/>\n    single agent.\n  <\/p>\n<p>\n    Adverse reactions occurring in patients with recurrent or metastatic cSCC or<br \/>\n    locally advanced cSCC were similar to those occurring in patients with<br \/>\n    melanoma or NSCLC who received KEYTRUDA as a monotherapy.\n  <\/p>\n<p>\n    In KEYNOTE-522, when KEYTRUDA was administered with neoadjuvant chemotherapy<br \/>\n    (carboplatin and paclitaxel followed by doxorubicin or epirubicin and<br \/>\n    cyclophosphamide) followed by surgery and continued adjuvant treatment with<br \/>\n    KEYTRUDA as a single agent (n=778) to patients with newly diagnosed,<br \/>\n    previously untreated, high-risk early-stage TNBC, fatal adverse reactions<br \/>\n    occurred in 0.9% of patients, including 1 each of adrenal crisis, autoimmune<br \/>\n    encephalitis, hepatitis, pneumonia, pneumonitis, pulmonary embolism, and<br \/>\n    sepsis in association with multiple organ dysfunction syndrome and myocardial<br \/>\n    infarction. Serious adverse reactions occurred in 44% of patients receiving<br \/>\n    KEYTRUDA; those \u22652% were febrile neutropenia (15%), pyrexia (3.7%), anemia<br \/>\n    (2.6%), and neutropenia (2.2%). KEYTRUDA was discontinued in 20% of patients<br \/>\n    due to adverse reactions. The most common reactions (\u22651%) resulting in<br \/>\n    permanent discontinuation were increased ALT (2.7%), increased AST (1.5%), and<br \/>\n    rash (1%). The most common adverse reactions (\u226520%) in patients receiving<br \/>\n    KEYTRUDA were fatigue (70%), nausea (67%), alopecia (61%), rash (52%),<br \/>\n    constipation (42%), diarrhea and peripheral neuropathy (41% each), stomatitis<br \/>\n    (34%), vomiting (31%), headache (30%), arthralgia (29%), pyrexia (28%), cough<br \/>\n    (26%), abdominal pain (24%), decreased appetite (23%), insomnia (21%), and<br \/>\n    myalgia (20%).\n  <\/p>\n<p>\n    In KEYNOTE-355, when KEYTRUDA and chemotherapy (paclitaxel, paclitaxel<br \/>\n    protein-bound, or gemcitabine and carboplatin) were administered to patients<br \/>\n    with locally recurrent unresectable or metastatic TNBC who had not been<br \/>\n    previously treated with chemotherapy in the metastatic setting (n=596), fatal<br \/>\n    adverse reactions occurred in 2.5% of patients, including cardio-respiratory<br \/>\n    arrest (0.7%) and septic shock (0.3%). Serious adverse reactions occurred in<br \/>\n    30% of patients receiving KEYTRUDA in combination with chemotherapy; the<br \/>\n    serious reactions in \u22652% were pneumonia (2.9%), anemia (2.2%), and<br \/>\n    thrombocytopenia (2%). KEYTRUDA was discontinued in 11% of patients due to<br \/>\n    adverse reactions. The most common reactions resulting in permanent<br \/>\n    discontinuation (\u22651%) were increased ALT (2.2%), increased AST (1.5%), and<br \/>\n    pneumonitis (1.2%). The most common adverse reactions (\u226520%) in patients<br \/>\n    receiving KEYTRUDA in combination with chemotherapy were fatigue (48%), nausea<br \/>\n    (44%), alopecia (34%), diarrhea and constipation (28% each), vomiting and rash<br \/>\n    (26% each), cough (23%), decreased appetite (21%), and headache (20%).\n  <\/p>\n<p><strong>Lactation<\/strong><\/p>\n<p>\n    Because of the potential for serious adverse reactions in breastfed children,<br \/>\n    advise women not to breastfeed during treatment and for 4 months after the<br \/>\n    last dose.\n  <\/p>\n<p><strong>Pediatric Use<\/strong><\/p>\n<p>\n    In KEYNOTE-051, 173 pediatric patients (65 pediatric patients aged 6 months to<br \/>\n    younger than 12 years and 108 pediatric patients aged 12 years to 17 years)<br \/>\n    were administered KEYTRUDA 2 mg\/kg every 3 weeks. The median duration of<br \/>\n    exposure was 2.1 months (range: 1 day to 25 months).\n  <\/p>\n<p>\n    Adverse reactions that occurred at a \u226510% higher rate in pediatric patients<br \/>\n    when compared to adults were pyrexia (33%), leukopenia (31%), vomiting (29%),<br \/>\n    neutropenia (28%), headache (25%), abdominal pain (23%), thrombocytopenia<br \/>\n    (22%), anemia (17%), decreased lymphocyte count (13%), and decreased white<br \/>\n    blood cell count (11%).\n  <\/p>\n<p><strong>Additional Indications for KEYTRUDA in the U.S.<\/strong><\/p>\n<p><em>Non-Small Cell Lung Cancer<\/em><\/p>\n<p>\n    KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is<br \/>\n    indicated for the first-line treatment of patients with metastatic nonsquamous<br \/>\n    non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor<br \/>\n    aberrations.\n  <\/p>\n<p>\n    KEYTRUDA, in combination with carboplatin and either paclitaxel or paclitaxel<br \/>\n    protein-bound, is indicated for the first-line treatment of patients with<br \/>\n    metastatic squamous NSCLC.\n  <\/p>\n<p>\n    KEYTRUDA, as a single agent, is indicated for the first-line treatment of<br \/>\n    patients with NSCLC expressing PD-L1 [tumor proportion score (TPS) \u22651%] as<br \/>\n    determined by an FDA-approved test, with no EGFR or ALK genomic tumor<br \/>\n    aberrations, and is:\n  <\/p>\n<ul>\n<li>\n      stage III where patients are not candidates for surgical resection or<br \/>\n      definitive chemoradiation, or\n    <\/li>\n<li>metastatic.<\/li>\n<\/ul>\n<p>\n    KEYTRUDA, as a single agent, is indicated for the treatment of patients with<br \/>\n    metastatic NSCLC whose tumors express PD-L1 (TPS \u22651%) as determined by an<br \/>\n    FDA-approved test, with disease progression on or after platinum-containing<br \/>\n    chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have<br \/>\n    disease progression on FDA-approved therapy for these aberrations prior to<br \/>\n    receiving KEYTRUDA.\n  <\/p>\n<p>\n    KEYTRUDA, as a single agent, is indicated as adjuvant treatment following<br \/>\n    resection and platinum-based chemotherapy for adult patients with stage IB<br \/>\n    (T2a \u22654 cm), II, or IIIA NSCLC.\n  <\/p>\n<p><em>Head and Neck Squamous Cell Cancer<\/em><\/p>\n<p>\n    KEYTRUDA, in combination with platinum and fluorouracil (FU), is indicated for<br \/>\n    the first-line treatment of patients with metastatic or with unresectable,<br \/>\n    recurrent head and neck squamous cell carcinoma (HNSCC).\n  <\/p>\n<p>\n    KEYTRUDA, as a single agent, is indicated for the first-line treatment of<br \/>\n    patients with metastatic or with unresectable, recurrent HNSCC whose tumors<br \/>\n    express PD-L1 [Combined Positive Score (CPS) \u22651] as determined by an<br \/>\n    FDA-approved test.\n  <\/p>\n<p>\n    KEYTRUDA, as a single agent, is indicated for the treatment of patients with<br \/>\n    recurrent or metastatic HNSCC with disease progression on or after<br \/>\n    platinum-containing chemotherapy.\n  <\/p>\n<p><em>Classical Hodgkin Lymphoma<\/em><\/p>\n<p>\n    KEYTRUDA is indicated for the treatment of adult patients with relapsed or<br \/>\n    refractory classical Hodgkin lymphoma (cHL).\n  <\/p>\n<p>\n    KEYTRUDA is indicated for the treatment of pediatric patients with refractory<br \/>\n    cHL, or cHL that has relapsed after 2 or more lines of therapy.\n  <\/p>\n<p><em>Primary Mediastinal Large B-Cell Lymphoma<\/em><\/p>\n<p>\n    KEYTRUDA is indicated for the treatment of adult and pediatric patients with<br \/>\n    refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have<br \/>\n    relapsed after 2 or more prior lines of therapy. KEYTRUDA is not recommended<br \/>\n    for treatment of patients with PMBCL who require urgent cytoreductive therapy.\n  <\/p>\n<p><em>Urothelial Carcinoma<\/em><\/p>\n<p>\n    KEYTRUDA, in combination with enfortumab vedotin, is indicated for the<br \/>\n    treatment of adult patients with locally advanced or metastatic urothelial<br \/>\n    carcinoma (mUC) who are not eligible for cisplatin-containing chemotherapy.\n  <\/p>\n<p>\n    This indication is approved under accelerated approval based on tumor response<br \/>\n    rate and durability of response. Continued approval for this indication may be<br \/>\n    contingent upon verification and description of clinical benefit in the<br \/>\n    confirmatory trials.\n  <\/p>\n<p>\n    KEYTRUDA, as a single agent, is indicated for the treatment of patients with<br \/>\n    locally advanced or metastatic urothelial carcinoma (mUC):\n  <\/p>\n<ul>\n<li>who are not eligible for any platinum-containing chemotherapy, or<\/li>\n<li>\n      who have disease progression during or following platinum-containing<br \/>\n      chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with<br \/>\n      platinum-containing chemotherapy.\n    <\/li>\n<\/ul>\n<p>\n    KEYTRUDA, as a single agent, is indicated for the treatment of patients with<br \/>\n    Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive<br \/>\n    bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary<br \/>\n    tumors who are ineligible for or have elected not to undergo cystectomy.\n  <\/p>\n<p>\n    <em>Microsatellite Instability-High or Mismatch Repair Deficient Cancer<\/em>\n  <\/p>\n<p>\n    KEYTRUDA is indicated for the treatment of adult and pediatric patients with<br \/>\n    unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch<br \/>\n    repair deficient (dMMR) solid tumors, as determined by an FDA-approved test,<br \/>\n    that have progressed following prior treatment and who have no satisfactory<br \/>\n    alternative treatment options.\n  <\/p>\n<p>\n    <em>Microsatellite Instability-High or Mismatch Repair Deficient Colorectal<br \/>\n      Cancer<\/em>\n  <\/p>\n<p>\n    KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n    metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an<br \/>\n    FDA-approved test.\n  <\/p>\n<p><em>Gastric Cancer<\/em><\/p>\n<p>\n    KEYTRUDA, in combination with trastuzumab, fluoropyrimidine- and<br \/>\n    platinum-containing chemotherapy, is indicated for the first-line treatment of<br \/>\n    patients with locally advanced unresectable or metastatic HER2-positive<br \/>\n    gastric or gastroesophageal junction (GEJ) adenocarcinoma.\n  <\/p>\n<p>\n    This indication is approved under accelerated approval based on tumor response<br \/>\n    rate and durability of response. Continued approval for this indication may be<br \/>\n    contingent upon verification and description of clinical benefit in the<br \/>\n    confirmatory trials.\n  <\/p>\n<p><em>Esophageal Cancer<\/em><\/p>\n<p>\n    KEYTRUDA is indicated for the treatment of patients with locally advanced or<br \/>\n    metastatic esophageal or gastroesophageal junction (GEJ) (tumors with<br \/>\n    epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to<br \/>\n    surgical resection or definitive chemoradiation either:\n  <\/p>\n<ul>\n<li>\n      in combination with platinum- and fluoropyrimidine-based chemotherapy, or\n    <\/li>\n<li>\n      as a single agent after one or more prior lines of systemic therapy for<br \/>\n      patients with tumors of squamous cell histology that express PD-L1 (CPS<br \/>\n      \u226510) as determined by an FDA-approved test.\n    <\/li>\n<\/ul>\n<p><em>Cervical Cancer<\/em><\/p>\n<p>\n    KEYTRUDA, in combination with chemotherapy, with or without bevacizumab, is<br \/>\n    indicated for the treatment of patients with persistent, recurrent, or<br \/>\n    metastatic cervical cancer whose tumors express PD-L1 (CPS \u22651) as<br \/>\n    determined by an FDA-approved test.\n  <\/p>\n<p>\n    KEYTRUDA, as a single agent, is indicated for the treatment of patients with<br \/>\n    recurrent or metastatic cervical cancer with disease progression on or after<br \/>\n    chemotherapy whose tumors express PD-L1 (CPS \u22651) as determined by an<br \/>\n    FDA-approved test.\n  <\/p>\n<p><em>Hepatocellular Carcinoma<\/em><\/p>\n<p>\n    KEYTRUDA is indicated for the treatment of patients with hepatocellular<br \/>\n    carcinoma (HCC) who have been previously treated with sorafenib. This<br \/>\n    indication is approved under accelerated approval based on tumor response rate<br \/>\n    and durability of response. Continued approval for this indication may be<br \/>\n    contingent upon verification and description of clinical benefit in the<br \/>\n    confirmatory trials.\n  <\/p>\n<p><em>Merkel Cell Carcinoma<\/em><\/p>\n<p>\n    KEYTRUDA is indicated for the treatment of adult and pediatric patients with<br \/>\n    recurrent locally advanced or metastatic Merkel cell carcinoma (MCC). This<br \/>\n    indication is approved under accelerated approval based on tumor response rate<br \/>\n    and durability of response. Continued approval for this indication may be<br \/>\n    contingent upon verification and description of clinical benefit in the<br \/>\n    confirmatory trials.\n  <\/p>\n<p><em>Renal Cell Carcinoma<\/em><\/p>\n<p>\n    KEYTRUDA, in combination with axitinib, is indicated for the first-line<br \/>\n    treatment of adult patients with advanced renal cell carcinoma (RCC).\n  <\/p>\n<p>\n    KEYTRUDA is indicated for the adjuvant treatment of patients with RCC at<br \/>\n    intermediate-high or high risk of recurrence following nephrectomy, or<br \/>\n    following nephrectomy and resection of metastatic lesions.\n  <\/p>\n<p><em>Endometrial Carcinoma<\/em><\/p>\n<p>\n    KEYTRUDA, as a single agent, is indicated for the treatment of patients with<br \/>\n    advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an<br \/>\n    FDA-approved test, who have disease progression following prior systemic<br \/>\n    therapy in any setting and are not candidates for curative surgery or<br \/>\n    radiation.\n  <\/p>\n<p><em>Tumor Mutational Burden-High Cancer<\/em><\/p>\n<p>\n    KEYTRUDA is indicated for the treatment of adult and pediatric patients with<br \/>\n    unresectable or metastatic tumor mutational burden-high (TMB-H) [\u226510<br \/>\n    mutations\/megabase] solid tumors, as determined by an FDA-approved test, that<br \/>\n    have progressed following prior treatment and who have no satisfactory<br \/>\n    alternative treatment options. This indication is approved under accelerated<br \/>\n    approval based on tumor response rate and durability of response. Continued<br \/>\n    approval for this indication may be contingent upon verification and<br \/>\n    description of clinical benefit in the confirmatory trials. The safety and<br \/>\n    effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous<br \/>\n    system cancers have not been established.\n  <\/p>\n<p><em>Cutaneous Squamous Cell Carcinoma<\/em><\/p>\n<p>\n    KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n    metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC<br \/>\n    that is not curable by surgery or radiation.\n  <\/p>\n<p><em>Triple-Negative Breast Cancer<\/em><\/p>\n<p>\n    KEYTRUDA is indicated for the treatment of patients with high-risk early-stage<br \/>\n    triple-negative breast cancer (TNBC) in combination with chemotherapy as<br \/>\n    neoadjuvant treatment, and then continued as a single agent as adjuvant<br \/>\n    treatment after surgery.\n  <\/p>\n<p>\n    KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of<br \/>\n    patients with locally recurrent unresectable or metastatic TNBC whose tumors<br \/>\n    express PD-L1 (CPS \u226510) as determined by an FDA-approved test.\n  <\/p>\n<p><strong>Merck\u2019s focus on cancer<\/strong><\/p>\n<p>\n    Our goal is to translate breakthrough science into innovative oncology<br \/>\n    medicines to help people with cancer worldwide. At Merck, the potential to<br \/>\n    bring new hope to people with cancer drives our purpose and supporting<br \/>\n    accessibility to our cancer medicines is our commitment. As part of our focus<br \/>\n    on cancer, Merck is committed to exploring the potential of immuno-oncology<br \/>\n    with one of the largest development programs in the industry across more than<br \/>\n    30 tumor types. We also continue to strengthen our portfolio through strategic<br \/>\n    acquisitions and are prioritizing the development of several promising<br \/>\n    oncology candidates with the potential to improve the treatment of advanced<br \/>\n    cancers. For more information about our oncology clinical trials, visit<br \/>\n    <a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/clinicaltrials\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n  <\/p>\n<p><strong>About Merck<\/strong><\/p>\n<p>\n    At Merck, known as MSD outside of the United States and Canada, we are unified<br \/>\n    around our purpose: We use the power of leading-edge science to save and<br \/>\n    improve lives around the world. For more than 130 years, we have brought hope<br \/>\n    to humanity through the development of important medicines and vaccines. We<br \/>\n    aspire to be the premier research-intensive biopharmaceutical company in the<br \/>\n    world \u2013 and today, we are at the forefront of research to deliver<br \/>\n    innovative health solutions that advance the prevention and treatment of<br \/>\n    diseases in people and animals. We foster a diverse and inclusive global<br \/>\n    workforce and operate responsibly every day to enable a safe, sustainable and<br \/>\n    healthy future for all people and communities.&nbsp;For more information,<br \/>\n    visit&nbsp;<a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/\">vip2-msd.com\/merckcom-migrated<\/a>&nbsp;and connect<br \/>\n    with us on&nbsp;<a href=\"https:\/\/twitter.com\/Merck\">Twitter<\/a>,&nbsp;<a href=\"https:\/\/www.facebook.com\/MerckInvents\/\">Facebook<\/a>,&nbsp;<a href=\"https:\/\/www.instagram.com\/merck\/\">Instagram<\/a>,&nbsp;<a href=\"http:\/\/www.youtube.com\/Merck\">YouTube<\/a>&nbsp;and&nbsp;<a href=\"https:\/\/www.linkedin.com\/company\/merck\">LinkedIn<\/a>.\n  <\/p>\n<p><strong>About Moderna<\/strong><\/p>\n<p>\n    In over 10 years since its inception, Moderna has transformed from a<br \/>\n    research-stage company advancing programs in the field of messenger RNA<br \/>\n    (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and<br \/>\n    therapeutics across seven modalities, a broad intellectual property portfolio<br \/>\n    and integrated manufacturing facilities that allow for rapid clinical and<br \/>\n    commercial production at scale. Moderna maintains alliances with a broad range<br \/>\n    of domestic and overseas government and commercial collaborators, which has<br \/>\n    allowed for the pursuit of both groundbreaking science and rapid scaling of<br \/>\n    manufacturing. Most recently, Moderna\u2019s capabilities have come together<br \/>\n    to allow the authorized use and approval of one of the earliest and most<br \/>\n    effective vaccines against the COVID-19 pandemic.\n  <\/p>\n<p>\n    Moderna\u2019s mRNA platform builds on continuous advances in basic and<br \/>\n    applied mRNA science, delivery technology and manufacturing, and has allowed<br \/>\n    the development of therapeutics and vaccines for infectious diseases,<br \/>\n    immuno-oncology, rare diseases, cardiovascular diseases and auto-immune<br \/>\n    diseases. Moderna has been named a top biopharmaceutical employer by<br \/>\n    <em>Science<\/em> for the past eight years. To learn more, visit<br \/>\n    <a href=\"http:\/\/www.modernatx.com\">www.modernatx.com<\/a>.\n  <\/p>\n<p><strong>Moderna\u2019s focus on cancer<\/strong><\/p>\n<p>\n    At Moderna, we are delivering on the promise of mRNA science to create a new<br \/>\n    generation of transformative medicines for patients. We are relentlessly<br \/>\n    working to grow our cancer therapeutic modality by discovering mRNA medicines<br \/>\n    that harness the body\u2019s immune system to identify and kill cancer cells<br \/>\n    in the same way the immune system identifies and targets infections. One<br \/>\n    example of a promising oncology candidate is the creation of individualized,<br \/>\n    mRNA-based cancer therapies. We also continue to strengthen our portfolio<br \/>\n    through strategic collaborations that increase our potential to improve<br \/>\n    treatment options for patients with cancer.\n  <\/p>\n<p>\n    <strong>Forward-Looking Statement of Merck &amp; Co., Inc., Rahway, N.J.,<br \/>\n      USA<\/strong>\n  <\/p>\n<p>\n    This news release of Merck &amp; Co., Inc., Rahway, N.J., USA (the<br \/>\n    \u201ccompany\u201d) includes \u201cforward-looking statements\u201d<br \/>\n    within the meaning of the safe harbor provisions of the U.S. Private<br \/>\n    Securities Litigation Reform Act of 1995. These statements are based upon the<br \/>\n    current beliefs and expectations of the company\u2019s management and are<br \/>\n    subject to significant risks and uncertainties. There can be no guarantees<br \/>\n    with respect to pipeline candidates that the candidates will receive the<br \/>\n    necessary regulatory approvals or that they will prove to be commercially<br \/>\n    successful. If underlying assumptions prove inaccurate or risks or<br \/>\n    uncertainties materialize, actual results may differ materially from those set<br \/>\n    forth in the forward-looking statements.\n  <\/p>\n<p>\n    Risks and uncertainties include but are not limited to, general industry<br \/>\n    conditions and competition; general economic factors, including interest rate<br \/>\n    and currency exchange rate fluctuations; the impact of the global outbreak of<br \/>\n    novel coronavirus disease (COVID-19); the impact of pharmaceutical industry<br \/>\n    regulation and health care legislation in the United States and<br \/>\n    internationally; global trends toward health care cost containment;<br \/>\n    technological advances, new products and patents attained by competitors;<br \/>\n    challenges inherent in new product development, including obtaining regulatory<br \/>\n    approval; the company\u2019s ability to accurately predict future market<br \/>\n    conditions; manufacturing difficulties or delays; financial instability of<br \/>\n    international economies and sovereign risk; dependence on the effectiveness of<br \/>\n    the company\u2019s patents and other protections for innovative products; and<br \/>\n    the exposure to litigation, including patent litigation, and\/or regulatory<br \/>\n    actions.\n  <\/p>\n<p>\n    The company undertakes no obligation to publicly update any forward-looking<br \/>\n    statement, whether as a result of new information, future events or otherwise.<br \/>\n    Additional factors that could cause results to differ materially from those<br \/>\n    described in the forward-looking statements can be found in the<br \/>\n    company\u2019s Annual Report on Form 10-K for the year ended December 31,<br \/>\n    2022 and the company\u2019s other filings with the Securities and Exchange<br \/>\n    Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/www.sec.gov\/\">www.sec.gov<\/a>).\n  <\/p>\n<p><strong>Moderna Forward-Looking Statements<\/strong><\/p>\n<p>\n    This press release contains forward-looking statements within the meaning of<br \/>\n    the Private Securities Litigation Reform Act of 1995, as amended, including<br \/>\n    regarding: the development by Moderna and Merck of an individualized<br \/>\n    neoantigen therapy (mRNA-4157 (V940)); plans to initiate a Phase 3 study in<br \/>\n    the adjuvant setting in patients with high-risk melanoma in 2023 and to<br \/>\n    rapidly expand to additional tumor types, including non-small cell lung<br \/>\n    cancer; the ability and potential for mRNA-4157 (V940) to improve distant<br \/>\n    metastasis-free survival (DMFS) patients with high-risk stage III\/IV melanoma;<br \/>\n    the tolerability and safety profile for mRNA-4157 (V940); the potential for<br \/>\n    mRNA, including mRNA-4157, to effectively treat different types of cancer; the<br \/>\n    potential development of individualized, mRNA-based cancer therapies; the<br \/>\n    ability of an individualized neoantigen therapy to trigger a tailored<br \/>\n    antitumor response specific to a patient\u2019s tumor mutation signature; and<br \/>\n    the potential for expedited regulatory approval and commercialization of<br \/>\n    mRNA-4157 (V940). The forward-looking statements in this press release are<br \/>\n    neither promises nor guarantees, and you should not place undue reliance on<br \/>\n    these forward-looking statements because they involve known and unknown risks,<br \/>\n    uncertainties, and other factors, many of which are beyond Moderna&#8217;s control<br \/>\n    and which could cause actual results to differ materially from those expressed<br \/>\n    or implied by these forward-looking statements. These risks, uncertainties,<br \/>\n    and other factors include those other risks and uncertainties described under<br \/>\n    the heading &#8220;Risk Factors&#8221; in Moderna&#8217;s most recent Annual Report on Form 10-K<br \/>\n    for the year ended December 31, 2022, filed with the U.S. Securities and<br \/>\n    Exchange Commission (SEC) and in subsequent filings made by Moderna with the<br \/>\n    SEC, which are available on the SEC&#8217;s website at www.sec.gov. Except as<br \/>\n    required by law, Moderna disclaims any intention or responsibility for<br \/>\n    updating or revising any forward-looking statements contained in this press<br \/>\n    release in the event of new information, future developments or otherwise.<br \/>\n    These forward-looking statements are based on Moderna&#8217;s current expectations<br \/>\n    and speak only as of the date of this press release.\n  <\/p>\n<p style=\"text-align: center\">###<\/p>\n<p>\n    <strong>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at <\/strong><a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf\"><strong>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/strong><\/a><strong> and Medication Guide for KEYTRUDA at <\/strong><a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf\"><strong>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/strong><\/a><strong>.&nbsp;<\/strong>\n  <\/p>\n<p>\n    Individualized neoantigen therapy&nbsp;was previously referred to as a<br \/>\n    personalized cancer vaccine, or PCV.\n  <\/p>\n<table cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td>\n<p>Moderna Media Contacts:<\/p>\n<\/td>\n<td>\n<p>Colleen Hussey<\/p>\n<p>Senior Director, Brand &amp; Corporate Affairs<\/p>\n<p>\n            <a href=\"mailto:colleen.hussey@modernatx.com\">colleen.hussey@modernatx.com<\/a>\n          <\/p>\n<p>617-335-1374<\/p>\n<\/td>\n<td>\n<p>Moderna Investor Contacts:<\/p>\n<\/td>\n<td>\n<p>Lavina Talukdar<\/p>\n<p>Senior Vice President &amp; Head of Investor Relations<\/p>\n<p><a href=\"mailto:lavina.talukdar@modernatx.com\">lavina.talukdar@modernatx.com<\/a><\/p>\n<p><a href=\"lavina.talukdar@modernatx.com\"><\/a><\/p>\n<p>617-209-5834<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>Merck Media Contacts:<\/p>\n<\/td>\n<td>\n<p>Julie Cunningham<\/p>\n<p>(617) 519-6264<\/p>\n<p>Sienna Choi<\/p>\n<p>(908) 873-4311<\/p>\n<\/td>\n<td>\n<p>Merck Investor Contacts:<\/p>\n<\/td>\n<td>\n<p>Peter Dannenbaum<\/p>\n<p>(732) 594-1579<\/p>\n<p>Damini Chokshi<\/p>\n<p>(732) 594-1577<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of distant metastasis or death by 65% (HR=0.347 [95% CI, 0.145-0.828]); one-sided p value=0.0063) compared to KEYTRUDA alone The DMFS results, a key secondary endpoint of the Phase 2b KEYNOTE-942 study, will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Companies plan to initiate a Phase 3 study in the adjuvant setting in patients with high-risk melanoma in 2023, and rapidly expand to additional tumor types, including non-small cell lung cancer CAMBRIDGE, M.A. &amp; RAHWAY, N.J., June 5, 2023 \u2013 Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced distant metastasis-free survival (DMFS) results from the Phase 2b randomized KEYNOTE-942\/mRNA-4157-P201 study, a clinical trial evaluating mRNA-4157 (V940), an investigational individualized<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,289,56],"class_list":["post-3622057","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA\u00ae (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival (DMFS) in Patients with High-Risk Stage III\/IV Melanoma Following Complete Resection Versus KEYTRUDA - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/moderna-and-merck-announce-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-a-statistically-significant-and-clinically-meaningful-improvement-in-distant-metastasis-free\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA\u00ae (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival (DMFS) in Patients with High-Risk Stage III\/IV Melanoma Following Complete Resection Versus KEYTRUDA - Merck.com\" \/>\n<meta property=\"og:description\" content=\"mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of distant metastasis or death by 65% (HR=0.347 [95% CI, 0.145-0.828]); one-sided p value=0.0063) compared to KEYTRUDA alone The DMFS results, a key secondary endpoint of the Phase 2b KEYNOTE-942 study, will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Companies plan to initiate a Phase 3 study in the adjuvant setting in patients with high-risk melanoma in 2023, and rapidly expand to additional tumor types, including non-small cell lung cancer CAMBRIDGE, M.A. &amp; RAHWAY, N.J., June 5, 2023 \u2013 Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced distant metastasis-free survival (DMFS) results from the Phase 2b randomized KEYNOTE-942\/mRNA-4157-P201 study, a clinical trial evaluating mRNA-4157 (V940), an investigational individualized\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/moderna-and-merck-announce-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-a-statistically-significant-and-clinically-meaningful-improvement-in-distant-metastasis-free\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-08T04:41:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"44 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/moderna-and-merck-announce-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-a-statistically-significant-and-clinically-meaningful-improvement-in-distant-metastasis-free\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/moderna-and-merck-announce-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-a-statistically-significant-and-clinically-meaningful-improvement-in-distant-metastasis-free\\\/\",\"name\":\"Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA\u00ae (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival (DMFS) in Patients with High-Risk Stage III\\\/IV Melanoma Following Complete Resection Versus KEYTRUDA - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2023-06-05T12:00:00+00:00\",\"dateModified\":\"2025-03-08T04:41:07+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/moderna-and-merck-announce-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-a-statistically-significant-and-clinically-meaningful-improvement-in-distant-metastasis-free\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/moderna-and-merck-announce-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-a-statistically-significant-and-clinically-meaningful-improvement-in-distant-metastasis-free\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/moderna-and-merck-announce-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-a-statistically-significant-and-clinically-meaningful-improvement-in-distant-metastasis-free\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA\u00ae (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival (DMFS) in Patients with High-Risk Stage III\\\/IV Melanoma Following Complete Resection Versus KEYTRUDA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA\u00ae (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival (DMFS) in Patients with High-Risk Stage III\/IV Melanoma Following Complete Resection Versus KEYTRUDA - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/moderna-and-merck-announce-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-a-statistically-significant-and-clinically-meaningful-improvement-in-distant-metastasis-free\/","og_locale":"en_US","og_type":"article","og_title":"Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA\u00ae (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival (DMFS) in Patients with High-Risk Stage III\/IV Melanoma Following Complete Resection Versus KEYTRUDA - Merck.com","og_description":"mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of distant metastasis or death by 65% (HR=0.347 [95% CI, 0.145-0.828]); one-sided p value=0.0063) compared to KEYTRUDA alone The DMFS results, a key secondary endpoint of the Phase 2b KEYNOTE-942 study, will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Companies plan to initiate a Phase 3 study in the adjuvant setting in patients with high-risk melanoma in 2023, and rapidly expand to additional tumor types, including non-small cell lung cancer CAMBRIDGE, M.A. &amp; RAHWAY, N.J., June 5, 2023 \u2013 Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced distant metastasis-free survival (DMFS) results from the Phase 2b randomized KEYNOTE-942\/mRNA-4157-P201 study, a clinical trial evaluating mRNA-4157 (V940), an investigational individualized","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/moderna-and-merck-announce-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-a-statistically-significant-and-clinically-meaningful-improvement-in-distant-metastasis-free\/","og_site_name":"Merck.com","article_modified_time":"2025-03-08T04:41:07+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"44 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/moderna-and-merck-announce-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-a-statistically-significant-and-clinically-meaningful-improvement-in-distant-metastasis-free\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/moderna-and-merck-announce-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-a-statistically-significant-and-clinically-meaningful-improvement-in-distant-metastasis-free\/","name":"Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA\u00ae (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival (DMFS) in Patients with High-Risk Stage III\/IV Melanoma Following Complete Resection Versus KEYTRUDA - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2023-06-05T12:00:00+00:00","dateModified":"2025-03-08T04:41:07+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/moderna-and-merck-announce-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-a-statistically-significant-and-clinically-meaningful-improvement-in-distant-metastasis-free\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/moderna-and-merck-announce-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-a-statistically-significant-and-clinically-meaningful-improvement-in-distant-metastasis-free\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/moderna-and-merck-announce-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-a-statistically-significant-and-clinically-meaningful-improvement-in-distant-metastasis-free\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA\u00ae (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival (DMFS) in Patients with High-Risk Stage III\/IV Melanoma Following Complete Resection Versus KEYTRUDA"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"381d017b-a62b-42bd-92d9-eb4bce288da5","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Moderna-and-Merck-Announce-mRNA-4157-V940-in-Combination-With-KEYTRUDA-pembrolizumab-Demonstrated-a-Statistically-Significant-and-Cli-GF4U6.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/3622057","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/3622057\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=3622057"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=3622057"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}